Prophylaxis after exposure to Coxiella burnetii

Emerging Infectious Diseases

Volumn 14, Issue 10, 2008, Pages 1558-1566

  Moodie, Claire E ^a,b,c   Thompson, Herbert A ^a   Meltzer, Martin I ^a   Swerdlow, David L ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Massachusetts Division of Tuberculosis Prevention and Control   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; DOXYCYCLINE;

ARTICLE; COXIELLA BURNETII; DEATH; DRUG FATALITY; FEMALE; HUMAN; INFECTION PREVENTION; PREGNANCY; Q FEVER; RISK; TOXIC EPIDERMAL NECROLYSIS; UNSPECIFIED SIDE EFFECT;

ADULT; ANTI-BACTERIAL AGENTS; BIOTERRORISM; CHILD; COXIELLA BURNETII; DECISION TREES; DOXYCYCLINE; FEMALE; HEART DISEASES; HEART VALVE DISEASES; HUMANS; IMMUNOCOMPROMISED HOST; INFANT, NEWBORN; MALE; MODELS, BIOLOGICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; Q FEVER; RISK ASSESSMENT; RISK FACTORS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 54249133859     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1410.080576     Document Type: Article

References (38)

1. Health Protection Agency Center for Infections. Interim guidelines for action in the event of a deliberate release: Q fever. 2005. Version 1.4, revised 2007 Jun 18 [cited 2008 Aug 1]. Available from www.hpa.org.uk/webw/ HPAweb&HPAwebStandard/HPAweb_C/1195733766607?p=1192454969657
2. McQuiston JH, Childs JE. Q fever in humans and animals in the United States. Vector Borne Zoonotic Dis. 2002;2:179-91. DOI: 10.1089/15303660260613747
3. Kagawa FT, Wehner JH, Mohindra V. Q fever as a biological weapon. Semin Respir Infect. 2003;18:183-95.
4. United States Army Medical Research Institute for Infectious Diseases. Medical management of biological casualities handbook. 5th ed. Frederick (MD): The Institute; 2004.
5. Dupuis G, Petite J, Peter O, Vouilloz M. An important outbreak of human Q fever in a Swiss Alpine valley. Int J Epidemiol. 1987;16:282-7. DOI: 10.1093/ije/16.2.282
6. Franz DR, Jahrling PB, Friedlander AM, McClain DJ, Hoover DL, Bryne WR, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA. 1997;278:399-411. DOI: 10.1001/jama.278.5.399
7. Maurin M, Raoult D. Q fever. Clin Microbiol Rev. 1999;12:518-53.
8. Raoult D, Tissot-Dupont H, Foucault C, Gouvernet J, Fournier PE, Bernit E, et al. Q fever 1985-1998. Clinical and epidemiologic features of 1,383 infections. Medicine (Baltimore). 2000;79:109-23. DOI: 10.1097/00005792- 200003000-00005
9. Bossi P, Tegnell A, Baka A, van Loock F, Werner A, Hendriks J, et al. Bichat guidelines for the clinical management of Q fever and bioterrorism-related Q fever. Euro Surveill. 2004;9:E19-20.
10. Kermode M, Yong K, Hurley S, Marmion B. An economic evaluation of increased uptake in Q fever vaccination among meat and agricultural industry workers following implementation of the National Q Fever Management Program. Aust N Z J Public Health. 2003;27:390-8. DOI: 10.1111/j.1467-842X.2003.tb00415.x
11. Fournier PE, Marrie TJ, Raoult D. Diagnosis of Q fever. J Clin Microbiol. 1998;36:1823-34.
12. Cutler SJ, Paiba GA, Howells J, Morgan KL. Q fever - a forgotten disease? Lancet Infect Dis. 2002;2:717-8. DOI: 10.1016/S1473-3099(02)00448-6
13. Fenollar F, Fournier PE, Carrieri MP, Habib G, Messana T, Raoult D. Risks factors and prevention of Q fever endocarditis. Clin Infect Dis. 2001;33:312-6. DOI: 10.1086/321889
14. Maltezou HC, Raoult D. Q fever in children. Lancet Infect Dis. 2002;2:686-91. DOI: 10.1016/S1473-3099(02)00440-1
15. Raoult D, Houpikian P, Tissot DH, Riss JM. rditi-Djiane J, Brouqui P. Treatment of Q fever endocarditis: comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine. Arch Intern Med. 1999;159:167-73. DOI: 10.1001/archinte.159.2.167
16. Marmion BP, Storm PA, Ayres JG, Semendric L, Mathews L, Winslow W, et al. Long-term persistence of Coxiella burnetii after acute primary Q fever. QJM. 2005;98:7-20. DOI: 10.1093/qjmed/hci009
17. Raoult D, Fenollar F, Stein A. Q fever during pregnancy: diagnosis, treatment, and follow-up. Arch Intern Med. 2002;162:701-4. DOI:10.1001/archinte. 162.6.701
18. Centers for Disease Control and Prevention. Bioterrorism agents/diseases [cited 2006 Sep 9]. Available from http://www.bt.cdc.gov/agent/agentlist- category.asp#b
19. Benenson AS, Tigertt WD. Studies on Q fever in man. Trans Assoc Am Physicians. 1956;69:98-104.
20. Byrne WR. Chapter 26: Q fever. In: Zajtchuk R, editor. Textbook of military medicine: medical aspects of chemical and biological warfare. Washington: US Department of the Army, Surgeon General and the Borden Institute; 1997. p. 523-37.
21. Carcopino X, Raoult D, Bretelle F, Boubli L, Stein A. Managing Q fever during pregnancy: the benefits of long-term cotrimoxazole therapy. Clin Infect Dis. 2007;45:548-55. DOI: 10.1086/520661
22. Haddix AC, Hillis SD, Kassler WJ. The cost effectiveness of azithromycin for Chlamydia trachomatis infections in women. Sex Transm Dis. 1995;22:274-80. DOI: 10.1097/00007435-199509000-00002
23. Nuovo J, Menikow J, Paliescheskey M, King J, Mowers R. Cost-effectiveness analysis of five different antibiotic regimens for the treatment of uncomplicated Chlamydia trachomatis cervicitis. J Am Board Fam Pract. 1995;8:7-16.
24. Gomolin IH, Siami PF, Reuning-Scherer J, Haverstock DC, Heyd A. Efficacy and safety of ciprofloxacin oral suspension versus trimethoprim-sulfamethoxazole oral suspension for treatment of older women with acute urinary tract infection. J Am Geriatr Soc. 2001;49:1606-13. DOI: 10.1111/j.1532-5415.2001. 49268.x
25. DiRienzo AG, van Der HC, Finkelstein DM, Frame P, Bozzette SA, Tashima KT. Efficacy of trimethoprim-sulfamethoxazole for the prevention of bacterial infections in a randomized prophylaxis trial of patients with advanced HIV infection. AIDS Res Hum Retroviruses. 2002;18:89-94. DOI: 10.1089/ 08892220252779629
26. Franz DR, Jahrling PB, McClain DJ, Hoover DL, Byrne WR, Pavlin JA, et al. Clinical recognition and management of patients exposed to biological warfare agents. Clin Lab Med. 2001;21:435-73.
27. Marrie TJ. Coxiella burnetii pneumonia. Eur Respir J. 2003;21:713-9. DOI: 10.1183/09031936.03.00095403
28. Ayres JG, Flint N, Smith EG, et al. Post-infection fatigue syndrome following Q fever. QJM. 1998;91:105-23. DOI: 10.1093/qjmed/91.2.105
29. Marmion BP, Shannon M, Maddocks I, Storm P, Penttila I. Protracted debility and fatigue after acute Q fever. Lancet. 1996;347:977-8. DOI: 10.1016/S0140-6736(96)91469-5
30. Smith DL, Ayres JG, Blair I, Burge PS, Carpenter MJ, Caul EO, et al. A large Q fever outbreak in the West Midlands: clinical aspects. Respir Med. 1993;87:509-16. DOI: 10.1016/0954-6111(93)90006-L
31. Raoult D, Levy PY, Dupont HT, Chicheportiche C, Tamalet C, Gastaut JA, et al. Q fever and HIV infection. AIDS. 1993;7:81-6. DOI: 10.1097/00002030- 199301000-00012
32. Siegman-Igra Y, Kaufman O, Keysary A, Rzotkiewicz S, Shalit I. Q fever endocarditis in Israel and a worldwide review. Scand J Infect Dis. 1997;29:41-9.
33. Fowler RA, Sanders GD, Bravata DM, Nouri B, Gastwirth JM, Peterson D, et al. Cost-effectiveness of defending against bioterrorism: a comparison of vaccination and antibiotic prophylaxis against anthrax. Ann Intern Med. 2005;142:601-10.
34. Sabbaj J, Hoagland VL, Shih WJ. Multiclinic comparative study of norfloxacin and trimethoprim-sulfamethoxazole for treatment of urinary tract infections. Antimicrob Agents Chemother. 1985;27:297-301.
35. Talan DA, Stamm WE, Hooton TM, Moran DJ, Burke T, Travani A, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial. JAMA. 2000;283:1583-90. DOI: 10.1001/jama.283.12.1583
36. Kocak Z, Hatipoglu CA, Ertem G, Kinikli S, Tufan A, Irmak H, et al. Trimethoprim-sulfamethoxazole induced rash and fatal hematologic disorders. J Infect. 2006;52:e49-52. DOI: 10.1016/j.jinf.2005.05.008
37. See S, Mumford JM. Trimethoprim/sulfamethoxazole-induced toxic epidermal necrolysis. Ann Pharmacother. 2001;35:694-7. DOI: 10.1345/aph.10310
38. Fennelly KP, Davidow AL, Miller SL, Connell N, Ellner JJ. Airborne infection with Bacillus anthracis - from mills to mail. Emerg Infect Dis. 2004;10:996-1001.